Business Combination (Tables)

9 Months Ended

Dec. 31, 2024

Business Combinations [Abstract]

Schedule of assets acquired and liabilities assumed

The Company's preliminary allocation of the purchase price to the assets acquired, liabilities assumed, and noncontrolling interest recognized and redeemable as of the Closing Date were as follows:

(In thousands)
Cash and cash equivalents	$	-
Accounts receivable		117
Materials and supplies		538
Operating lease right-of-use		3,063
Prepaid expenses and other assets		266
Property, plant, and equipment		20,110
Intangible assets		11,130
Goodwill		10,434
Total assets acquired		45,658
Accounts payable		1,252
Accrued expenses and other liabilities		111
Lease liabilities		3,063
Deferred income taxes		4,668
Deferred revenue		556
Total liabilities assumed		9,650
Total fair value of net assets acquired		36,008
Less: redeemable noncontrolling interest		(17,644	)
Total purchase price	$	18,364

Schedule of net impact of the Acquisition on the Company's condensed consolidated statements of operations

The following is the net impact of the Amplex Acquisition on the Company's condensed consolidated statements of operations since the Closing Date:

	For the Three Months Ended December 31, 2024		For the Nine Months Ended December 31, 2024
	(In thousands)
Total revenue	$	2,968	$	6,415
Income (loss) from continuing operations	$	261	$	(5	)

Schedule of business acquisition, pro forma information

The following table represents the supplemental consolidated financial results of the Company on an unaudited pro forma basis, as if the acquisition had been consummated on April 1, 2023.

	(In thousands)
	For the Three Months Ended December 31,						For the Nine Months Ended December 31,
	2024 (Actual)			2023 (Pro Forma)			2024 (Pro Forma)			2023 (Pro Forma)
Revenue	$	2,968		$	2,780		$	8,825		$	8,275
Net loss from continuing operations attributable to common shareholders before dividends		(403	)		(1,487	)		(11,279	)		(3,969	)
Redeemable noncontrolling interest redemption value in excess of carrying value deemed dividend		(154	)		-			(154	)		-
Net loss from continuing operations attributable to common shareholders		(557	)		(1,487	)		(11,433	)		(3,969	)
Net income (loss) from discontinued operations attributable to common shareholders		279			(9,962	)		3,139			(15,745	)
Net loss attributable to common shareholders		(278	)		(11,449	)		(8,294	)		(19,714	)
Per share amounts:
Basic (loss) earnings per share from continuing operations attributable to common shareholders		(0.08	)		(0.20	)		(1.71	)		(0.54	)
Diluted (loss) earnings per share from continuing operations attributable to common shareholders		(0.08	)		(0.20	)		(1.71	)		(0.54	)
Basic earnings (loss) per share from discontinued operations attributable to common shareholders		0.04			(1.37	)		0.47			(2.16	)
Diluted earnings (loss) per share from discontinued operations attributable to common shareholders		0.04			(1.37	)		0.47			(2.16	)
Basic (loss) earnings per share attributable to common shareholders		(0.04	)		(1.57	)		(1.24	)		(2.70	)
Diluted (loss) income per share attributable to common shareholders		(0.04	)		(1.57	)		(1.24	)		(2.70	)

Schedule of noncash investing and financing activities

The following table represents the supplemental schedule of noncash investing and financing activities:

	(In thousands)
	For the Nine Months Ended December 31,
	2024			2023
Supplemental schedule of noncash investing and financing activities
Fair value of Amplex assets acquired	$	45,658		$	-
Less: redeemable noncontrolling interest		(17,644	)		-
Less: cash paid for Amplex common stock		(18,364	)		-
Amplex liabilities assumed	$	9,650		$	-